Virility Medical is focused on developing an innovative intimate skin patch aimed at addressing premature ejaculation. The patch incorporates an electronic module that delivers neuromuscular electrical stimulation through the skin to the surrounding muscles. This method is designed to help men manage and delay the onset of premature ejaculation, effectively treating male sexual dysfunction. By utilizing neuromodulation technology, Virility Medical aims to provide a discreet and effective solution for individuals seeking assistance with this common concern.
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.
Phytolon Ltd, located in Misgav, Israel, specializes in the development of technology for producing natural food colorants. Founded in 2000, the company utilizes baker's yeast cells as bio-factories to create these colorants through a fermentation process. Phytolon's innovative approach aims to provide sustainable and natural alternatives for the food and beverage industry, addressing the growing demand for clean-label products.
Developer of a federated learning and edge-computing platform designed to allow artificial intelligence (AI) /data-science developers to collaborate without sharing data or compromising data privacy. The company's platform distributed computing technologies AI models can quickly and continuously improve by learning from each new dataset and applying those learnings to the next, without requiring costly and risky data transfers, helping users to accelerate the creation and training of more accurate models that work consistently across different patient populations.
Private Equity Round in 2022
Fu-Gen is an independent power producer and renewable energy investor focused on developing a comprehensive renewable energy network. The company specializes in greenfield projects and invests in various stages of renewable energy initiatives, from pre-permit phases to operational wind and solar assets. Its portfolio includes solar, wind, and storage-based projects aimed at achieving grid parity. By optimizing these renewable energy assets, Fu-Gen supports the transition to a low-carbon economy in Europe while providing sustainable returns to its investors.
Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.
Mindspace Ltd. is a provider of high-end co-working office spaces, offering a range of options including open spaces, private offices, meeting rooms, and event spaces. Founded in 2013 and headquartered in Tel Aviv, Israel, the company operates additional locations in cities such as Herzliya, Warsaw, London, Washington, San Francisco, Berlin, Hamburg, and Munich. Mindspace caters to diverse clients, including entrepreneurs, freelancers, startups, and established enterprises, providing tailored work environments that enhance employee engagement and foster a sense of community. With a focus on beautifully designed spaces and personalized service, Mindspace serves small and medium-sized enterprises, offering fully serviced and bespoke workspaces that accommodate the evolving needs of modern businesses across 31 locations in 16 cities and 7 countries throughout Europe and the United States.
Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.
Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.
Lendbuzz, Inc. is a car financing platform based in Boston, Massachusetts, established in 2015. It specializes in providing car loans to individuals with limited U.S. credit history, including international students, expats, and foreign professionals. The company utilizes machine learning algorithms and data-intensive scoring technology to assess creditworthiness based on factors such as employment, education, and personal history, rather than traditional credit scores or the requirement of a Social Security Number. This innovative approach allows Lendbuzz to offer attractive loan terms to customers who are often overlooked by conventional lenders. Once approved, clients can purchase vehicles from any dealership and work toward building their U.S. credit history while managing their loans through an online platform.
Laguna Health
Seed Round in 2021
Laguna Health is a digital health insurance company that helps people realize their recovery potential. It was founded by Yoni Shtein and Yael Peled Adam in 2020 in Tel Aviv, Tel Aviv, Israel.
Edocate specializes in a simulation-based learning platform aimed at enhancing the education of medical professionals in chronic disease management. The platform offers virtual patient simulations, allowing users to engage in self-directed learning while developing practical skills. It is designed to accommodate the busy schedules of adult learners, integrating gamification elements and providing mobile and client access for ease of use. Additionally, Edocate facilitates ongoing training and assessment, enabling medical education providers to create and distribute their own case studies efficiently and cost-effectively. The focus on practice skills ultimately aims to improve the quality of care delivered by healthcare professionals.
Edocate specializes in a simulation-based learning platform aimed at enhancing the education of medical professionals in chronic disease management. The platform offers virtual patient simulations, allowing users to engage in self-directed learning while developing practical skills. It is designed to accommodate the busy schedules of adult learners, integrating gamification elements and providing mobile and client access for ease of use. Additionally, Edocate facilitates ongoing training and assessment, enabling medical education providers to create and distribute their own case studies efficiently and cost-effectively. The focus on practice skills ultimately aims to improve the quality of care delivered by healthcare professionals.
Private Equity Round in 2021
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists with notifications about their dosage activity, which can be monitored remotely through a patient profile's on MedMinder's website.
The company was founded in 2007 and is headquartered in Needham, Massachusetts.
Private Equity Round in 2021
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists with notifications about their dosage activity, which can be monitored remotely through a patient profile's on MedMinder's website.
The company was founded in 2007 and is headquartered in Needham, Massachusetts.
Developer of a federated learning and edge-computing platform designed to allow artificial intelligence (AI) /data-science developers to collaborate without sharing data or compromising data privacy. The company's platform distributed computing technologies AI models can quickly and continuously improve by learning from each new dataset and applying those learnings to the next, without requiring costly and risky data transfers, helping users to accelerate the creation and training of more accurate models that work consistently across different patient populations.
Developer of a federated learning and edge-computing platform designed to allow artificial intelligence (AI) /data-science developers to collaborate without sharing data or compromising data privacy. The company's platform distributed computing technologies AI models can quickly and continuously improve by learning from each new dataset and applying those learnings to the next, without requiring costly and risky data transfers, helping users to accelerate the creation and training of more accurate models that work consistently across different patient populations.
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.
BioSight Ltd. is a biopharmaceutical company focused on the development of innovative cancer-targeted chemotherapy pro-drugs. Founded in 1999 and based in Lod, Israel, BioSight specializes in creating treatments that minimize systemic toxicity while effectively delivering chemotherapy directly to cancer cells. One of its notable products is a non-toxic conjugate of cytarabine and asparagine designed for treating acute myeloid leukemia. The company's proprietary technology, S2DOT, supports its pipeline of targeted pro-drugs, aiming to revolutionize cancer treatment by enhancing efficacy and reducing side effects associated with traditional chemotherapy. Since its relaunch in 2009, BioSight has pursued advancements in the research and development of these targeted therapies.
Percepto is a developer of autonomous drone technology for inspection and surveillance. Drones hold the potential to disrupt multi-billion dollar industries including energy, security, insurance, agriculture, and more. Drones completely change the way inspection, measurement, surveillance, and deliveries are done today. Still, the main barrier to making them a must-have platform is the ability of drones to perform tasks autonomously. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the most deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring) the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.
Pixellot is a sports media company based in Tel Aviv, Israel, specialized in automatic production solutions for amateur and semi-professional sporting events. Founded in 2013 by experts in video and media technology, Pixellot has developed patented technology that utilizes an unmanned multi-camera system to provide comprehensive coverage of sports fields. This system, paired with advanced algorithms, allows for efficient video production and the automatic generation of highlights. The company streams over 11,000 live video hours monthly, catering to fans, players, and coaches across various platforms. With more than 2,000 systems deployed globally, Pixellot serves minor leagues, high schools, youth academies, and prominent clubs, including Bayern Munich and Real Sociedad. Its notable partnerships include ESPN and other major sports media organizations, enhancing its reach and impact in the sports broadcasting industry.
Redpin Therapeutics, Inc., gene therapy company, develops a chemo genetics platform for targeted cell therapies that address intractable diseases of the nervous system. It discovers and develops an ion channel-based chemo genetics platform that enables targeted cell activation/inhibition controlled by low doses of the anti-smoking drug Varenicline. Redpin Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
BioSight Ltd. is a biopharmaceutical company focused on the development of innovative cancer-targeted chemotherapy pro-drugs. Founded in 1999 and based in Lod, Israel, BioSight specializes in creating treatments that minimize systemic toxicity while effectively delivering chemotherapy directly to cancer cells. One of its notable products is a non-toxic conjugate of cytarabine and asparagine designed for treating acute myeloid leukemia. The company's proprietary technology, S2DOT, supports its pipeline of targeted pro-drugs, aiming to revolutionize cancer treatment by enhancing efficacy and reducing side effects associated with traditional chemotherapy. Since its relaunch in 2009, BioSight has pursued advancements in the research and development of these targeted therapies.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.
Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.
Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.
Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.
Lendbuzz, Inc. is a car financing platform based in Boston, Massachusetts, established in 2015. It specializes in providing car loans to individuals with limited U.S. credit history, including international students, expats, and foreign professionals. The company utilizes machine learning algorithms and data-intensive scoring technology to assess creditworthiness based on factors such as employment, education, and personal history, rather than traditional credit scores or the requirement of a Social Security Number. This innovative approach allows Lendbuzz to offer attractive loan terms to customers who are often overlooked by conventional lenders. Once approved, clients can purchase vehicles from any dealership and work toward building their U.S. credit history while managing their loans through an online platform.
ARTSaVIT is a biopharmaceuticals company developing a cancer drug.
Digma Medical is a clinical stage medical device company established in 2013, focused on innovating treatments for Type-2 Diabetes and related metabolic syndromes, including NASH. The company is developing the DiaGone™, an endoscopic and disposable device that employs advanced laser technology to treat the duodenum without the need for an implant. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to use the DiaGone™ to enhance the body's ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and other metabolic conditions, thereby improving their overall quality of life and health outcomes. Supported by prominent venture capital firms, Digma Medical is dedicated to advancing effective therapies for diabetes management.
Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.
BioSight Ltd. is a biopharmaceutical company focused on the development of innovative cancer-targeted chemotherapy pro-drugs. Founded in 1999 and based in Lod, Israel, BioSight specializes in creating treatments that minimize systemic toxicity while effectively delivering chemotherapy directly to cancer cells. One of its notable products is a non-toxic conjugate of cytarabine and asparagine designed for treating acute myeloid leukemia. The company's proprietary technology, S2DOT, supports its pipeline of targeted pro-drugs, aiming to revolutionize cancer treatment by enhancing efficacy and reducing side effects associated with traditional chemotherapy. Since its relaunch in 2009, BioSight has pursued advancements in the research and development of these targeted therapies.
Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.
Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.
Quiet Therapeutics Ltd. is a biotechnology company based in Ness Ziona, Israel, that specializes in the discovery and development of cancer therapies. Founded in 2009, the company utilizes its proprietary GAGomer technology, a nanoparticle-based delivery system, to specifically target tumor cells. This innovative approach allows for the delivery of therapeutic agents, including expression plasmids, RNA therapeutics, and small molecules, aimed at inducing the death of cancer cells. By focusing on oncology and inflammation, Quiet Therapeutics aims to expand the range of drug targets and improve treatment outcomes for patients.
cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.